Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Sarcoma 2Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 6Trastuzumab 5Nivolumab 5palbociclib 4Carboplatin 4Biopsy 4lenvatinib 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Immunoglobulin G 3Fulvestrant 3Cyclophosphamide 3Cetuximab 3trastuzumab deruxtecan 2tisotumab vedotin 2spartalizumab 2sargramostim 2gedatolisib 2fludarabine 2epacadostat 2capivasertib 2X-Rays 2Sunitinib 2Docetaxel 2Disulfides 2Cisplatin 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × ceralasertib × Head & Neck × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡